Last updated 2026-08-18
- Raised $24M Series B led by OurCrowd, Aug 2022
- Raised $5.5M Seed round, 2017
- Raised $400k grant led by NRC-IRAP, Apr 2020
Total raised
$30.9M
Stage
—
Founded
2017
Headcount
—
HQ
Vancouver, Canada
Sector
Biotechnology
About
SaNOtize Research & Development Corp. is a pharmaceutical company based in Vancouver, Canada, focused on commercializing products that utilize the antimicrobial properties of nitric oxide (NO) for health and wellness. The company has developed and patented a Nitric Oxide Releasing Solution platform technology (NORS™) to treat and prevent upper respiratory and topical infections. Their product pipeline includes a nitric oxide nasal spray (NONS) for COVID-19 and other respiratory infections, as well as topical products for various infections.
Funding history · 4 rounds · $30.9M total
2022-08
B Round
$24.0M
★ OurCrowdHorizons VenturesABC InternationalAgricultural Bank of China International
2020-04
Grant
$400K
★ NRC-IRAP
2020-03
A Round
$1.0M
★ OurCrowd
2017
Seed
$5.5M
Team · 9
Gilly Regev
Founder · Chief Strategy and Innovation Officer
Chris Miller
Founder · Chief Science Officer
Steven Basta
CEO
Gibb Clarke
Chief Financial Officer
Mikael Svensson
executives
Jose Casillas
executives
Craig Fraser
Chairman of the Board
Elaine Campbell
Board Member
Dan Suesskind
Board Member
Sectors & technology
Primary sector
Biotechnology
Technologies
Target customers
Business model
B2BB2C
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | sanotize.com |
|---|
Identifiers & details
| Founded | 2017 |
|---|